Press release
Edoxaban Tosilate Orally Disintegrating Tablets Market Revenue Share, Insights & Future Outlook
The global market for Edoxaban Tosilate Orally Disintegrating Tablets was valued at US$ 1828 million in 2024 and is projected to reach US$ 3998 million by 2031, growing at a CAGR of 12.0% during the forecast period.Edoxaban Tosilate Orally Disintegrating Tablets are anticoagulant medications designed to prevent and treat blood clot-related conditions, including deep vein thrombosis, pulmonary embolism, and stroke prevention in non-valvular atrial fibrillation. The active ingredient, edoxaban, is a direct Factor Xa inhibitor that interrupts the blood clotting cascade. These tablets rapidly disintegrate in the mouth without water, enhancing patient convenience and compliance, especially for those with swallowing difficulties.
Download Free Data: https://reports.valuates.com/request/sample/QYRE-Auto-24L14551/Global_Edoxaban_Tosilate_Orally_Disintegrating_Tablets_Market_Research_Report_2023?utm_source=Openpr&utm_medium=Referral
What is Driving the Growth of the Edoxaban Tosilate Orally Disintegrating Tablets Market?
The market growth is driven by the rising prevalence of thromboembolic disorders, growing geriatric population, increased awareness of anticoagulation therapy, and demand for user-friendly formulations that improve patient compliance.
How are Market Trends Influenced by Drug Delivery Innovations and Healthcare Access?
Advancements in drug delivery technologies, expansion of healthcare access in emerging economies, and the convenience of orally disintegrating tablets are fueling market adoption. Challenges such as high treatment costs, potential bleeding risks, and competition from alternative anticoagulants may restrain growth. Regulatory approvals and strategic collaborations among pharmaceutical companies are expected to shape market dynamics.
Which Companies Are Leading the Edoxaban Tosilate Orally Disintegrating Tablets Market?
The key players include Daiichi Sankyo, Menarini Group, Simcere Pharmaceutical, and Lunan Pharmaceutical Group.
Market Segmentation
By Type
• 30 mg
• 60 mg
• Other
By Application
• Hospital
• Clinic
Key Companies in the Market
• Daiichi Sankyo - Global pharmaceutical company specializing in cardiovascular and anticoagulant therapies.
• Menarini Group - Provides innovative anticoagulant formulations and global pharmaceutical solutions.
• Simcere Pharmaceutical - Focuses on developing and manufacturing oral medications including anticoagulants.
• Lunan Pharmaceutical Group - Produces pharmaceutical products with a focus on hospital and clinical applications.
View Full Report: https://reports.valuates.com/market-reports/QYRE-Auto-24L14551/global-edoxaban-tosilate-orally-disintegrating-tablets?utm_source=Openpr&utm_medium=Referral
Email Id:
Please reach us at sales@valuates.com
Address:
Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066
Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Edoxaban Tosilate Orally Disintegrating Tablets Market Revenue Share, Insights & Future Outlook here
News-ID: 4206336 • Views: …
More Releases from Valuates Reports
Laboratory Nonhuman Primates (NHPs) Market Revenue Share, Insights & Future Outl …
The global market for Laboratory Nonhuman Primates (NHPs) was valued at US$ 2622 million in 2024 and is projected to reach US$ 4438 million by 2031, growing at a CAGR of 7.9% during the forecast period.
Nonhuman primates (NHPs) are mammals including simians (monkeys and apes) and prosimians (lemurs), and they are the closest animal models to humans in terms of genetics, physiology, and behavior. Research on NHPs has enabled critical…
PEG Hydrogel-based Medical Device Market Revenue Share, Insights & Future Outloo …
Polyethylene glycol (PEG) materials offer solubility, good biocompatibility, non-toxicity, and low immunogenicity. They are widely used in medical treatments such as wound adhesion, hemostasis, leakage prevention, and adhesion prevention during surgical operations. PEG-based hydrogels can also serve as raw materials for medical devices implanted in the human body, replacing traditional plant-, animal-, or human-source materials.
When sprayed onto a wound, PEG-based hydrogel rapidly solidifies to prevent bleeding and infection, then degrades…
CO2 Laser Aesthetic Medical Device Market Revenue Share, Insights & Future Outlo …
The global market for CO2 Laser Aesthetic Medical Device was valued at US$ 139 million in the year 2024 and is projected to reach a revised size of US$ 230 million by 2031, growing at a CAGR of 7.6% during the forecast period.
According to research, the global market for medical devices is estimated at US$ 603 billion in 2023 and is projected to grow at a CAGR of 5% over…
5-Chlorothiophene-2-Carboxylic Acid Market Revenue Share, Insights & Future Outl …
The global market for 5-Chlorothiophene-2-Carboxylic Acid was valued at US$ 21.9 million in the year 2024 and is projected to reach a revised size of US$ 29.1 million by 2031, growing at a CAGR of 4.2% during the forecast period.
What is Driving the Growth of the 5-Chlorothiophene-2-Carboxylic Acid Market?
The increasing use of 5-Chlorothiophene-2-Carboxylic Acid as an intermediate in pharmaceuticals and organic synthesis is contributing to steady demand growth.
Download Free Data:…
More Releases for Edoxaban
Factor Xa Inhibitor Drugs Market Size in 7MM is expected to grow at a decent CAG …
DelveInsight's "Factor Xa Inhibitor Market Insights, Epidemiology, and Market Forecast- 2034" report delivers an in-depth understanding of the Factor Xa Inhibitor, historical and forecasted epidemiology as well as the Factor Xa Inhibitor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the Factor Xa Inhibitor Market Share @ Factor Xa Inhibitor Market Outlook- https://www.delveinsight.com/sample-request/factor-xa-inhibitor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from…
Edoxaban Tosilate Orally Disintegrating Tablets Market Size,Volume,Revenue Trend …
Global Info Research announces the release of the report "Global Edoxaban Tosilate Orally Disintegrating Tablets Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029" . The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across…
Edoxaban Tosylate API Market : Future Projections and Industry Insights of the 2 …
Los Angeles, United States,- The research study presented here is a brilliant compilation of different types of analysis of critical aspects of the global Edoxaban Tosylate API market. It sheds light on how the global Edoxaban Tosylate API market is expected to grow during the course of the forecast period. With SWOT analysis and Porter's Five Forces analysis, it gives a deep explanation of the strengths and weaknesses of the global…
Best Statistical Edoxaban Tosilate Orally Disintegrating Tablets Market Growth S …
The Worldwide Market Reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2030
The latest competent intelligence report published by WMR with the title "An Increase in Demand and Opportunities for Global Edoxaban Tosilate Orally Disintegrating Tablets Market 2023″ provides a sorted image of the Edoxaban Tosilate Orally Disintegrating Tablets industry by analysis of research and information collected from various sources that have…
AntiCoagulants Market in U.S. High trend Opportunities offers Future Business Gr …
AntiCoagulants Market in U.S. 2020-2027: According to a new report published by Allied Market Research, titled, "U.S. AntiCoagulants Market by Product (Betrixaban, Dabigatran, Edoxaban, Rivaroxaban, and Eliquis) and by Application (Cardiovascular Diseases, Coronary Artery Diseases, Cardiac Arrhythmia, Myocardial Infarction, Heart Valve Replacement, and Others) - Opportunities and Industry Forecasts, 2020-2027"
Anticoagulants are used to treat blood clotting. Blood clots are formed when platelets aggregate and protein binds to form a solid…
U.S. AntiCoagulants Market estimate to reach faster by year 2023 : Pfizer Inc., …
Anticoagulants are used to treat blood clotting. Blood clots are formed when platelets aggregate and protein binds to form a solid mass. However, blood clotting is essential to stop excessive bleeding in diseases such as hemophilia. Anticoagulants are used to treat clot formation by stopping the platelets aggregation.
The major factors that contribute to the growth of the U.S. Anticoagulants market include increase in prevalence of hematic diseases such as hemophilia,…
